Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009
Eric Van Cutsem(Universitair Ziekenhuis Leuven), Josep Tabernero(Universitat de Vic - Universitat Central de Catalunya), Alberto Sobrero(Marqués de Valdecilla University Hospital), Nikolaos Pavlidis(Democritus University of Thrace), Atsushi Ohtsu(National Cancer Center Hospital East), Thomas Gruenberger(Medical University of Vienna), Nadir Arber(Tel Aviv Sourasky Medical Center), Jordan Berlin(Dana-Farber Cancer Institute), Heinz‐Josef Lenz(University of Southern California), Ravit Geva(Tel Aviv University), Karin Haustermans(KU Leuven), Aimery de Gramont(Institut Hospitalier Franco Britannique), Fortunato Ciardiello(University of Naples Federico II), Bengt Glimelius(Uppsala University), Axel Grothey(Mayo Clinic in Arizona), Roberto Labianca(Ospedale Papa Giovanni XXIII), Michel Ducreux(Université Paris-Saclay), Bruce D. Minsky(Harvard University), Wolff Schmiegel(Universitätsklinikum Knappschaftskrankenhaus Bochum), Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), Andrés Cervantes(Universitat de València), R. Glynne Jones(Mount Vernon Hospital), P. Rougier(Hôpital Européen Georges-Pompidou), Bernard Nordlinger(Heidelberg University), CJH van de Velde(Leiden University Medical Center), Daniel G. Haller(American Society of Clinical Oncology), M. Dicato(Centre Hospitalier de Luxembourg), Eduardo Díaz‐Rubio(Hospital Clínico San Carlos)
Cited by 80
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k